10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Current status of preoperative risk assessment for posthepatectomy liver failure in patients with hepatocellular carcinoma

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Liver resection is an effective therapeutic option for patients with hepatocellular carcinoma. However, posthepatectomy liver failure (PHLF) remains a major cause of hepatectomy‐related mortality, and the accurate prediction of PHLF based on preoperative assessment of liver functional reserve is a critical issue. The definition of PHLF proposed by the International Study Group for Liver Surgery has gained acceptance as a standard grading criterion. Liver function can be estimated using a variety of parameters, including routine blood biochemical examinations, clinical scoring systems, dynamic liver function tests, liver stiffness and fibrosis markers, and imaging studies. The Child–Pugh score and model for end‐stage liver disease scores are conventionally used for estimating liver decompensation, although the alternatively developed albumin‐bilirubin score shows superior performance for predicting hepatic dysfunction. Indocyanine green clearance, a dynamic liver function test mostly used in Japan and other Asian countries, serves as a quantitative estimation of liver function reserve and helps determine indications for surgical procedures according to the estimated risk of PHLF. In an attempt to improve predictive accuracy, specific evaluation of liver fibrosis and portal hypertension has gained popularity, including liver stiffness measurements using ultrasonography or magnetic resonance elastography, as well as noninvasive fibrosis markers. Imaging modalities, including Tc‐99m‐labeled galactosyl serum albumin scintigraphy and gadolinium‐enhanced magnetic resonance imaging, are used for preoperative evaluation in combination with liver volume. This review aims to provide an overview of the usefulness of current options for the preoperative assessment of liver function in predicting PHLF.

          Abstract

          Posthepatectomy liver failure remains a major cause of hepatectomy‐related mortality, and the accurate prediction of PHLF based on preoperative assessment of liver functional reserve is a critical issue. Multiple studies have evaluated the predictive performance of various preoperative parameters, which are broadly categorized as clinical scores based on routine blood tests, dynamic liver function tests, liver stiffness and noninvasive fibrosis markers, liver function imaging, and biomarkers for portal hypertension. This review aims to provide an overview of the utility of current options for preoperative assessment of liver function and the performance of each parameter in predicting PHLF.

          Related collections

          Most cited references186

          • Record: found
          • Abstract: not found
          • Article: not found

          EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Hepatocellular carcinoma

            Hepatocellular carcinoma appears frequently in patients with cirrhosis. Surveillance by biannual ultrasound is recommended for such patients because it allows diagnosis at an early stage, when effective therapies are feasible. The best candidates for resection are patients with a solitary tumour and preserved liver function. Liver transplantation benefits patients who are not good candidates for surgical resection, and the best candidates are those within Milan criteria (solitary tumour ≤5 cm or up to three nodules ≤3 cm). Image-guided ablation is the most frequently used therapeutic strategy, but its efficacy is limited by the size of the tumour and its localisation. Chemoembolisation has survival benefit in asymptomatic patients with multifocal disease without vascular invasion or extrahepatic spread. Finally, sorafenib, lenvatinib, which is non-inferior to sorafenib, and regorafenib increase survival and are the standard treatments in advanced hepatocellular carcinoma. This Seminar summarises the scientific evidence that supports the current recommendations for clinical practice, and discusses the areas in which more research is needed.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

                Bookmark

                Author and article information

                Contributors
                tnishio@kuhp.kyoto-u.ac.jp
                Journal
                Ann Gastroenterol Surg
                Ann Gastroenterol Surg
                10.1002/(ISSN)2475-0328
                AGS3
                Annals of Gastroenterological Surgery
                John Wiley and Sons Inc. (Hoboken )
                2475-0328
                21 May 2023
                November 2023
                : 7
                : 6 ( doiID: 10.1002/ags3.v7.6 )
                : 871-886
                Affiliations
                [ 1 ] Department of Surgery, Graduate School of Medicine Kyoto University Kyoto Japan
                [ 2 ] Department of Gastroenterological Surgery and Oncology Kitano Hospital Osaka Japan
                Author notes
                [*] [* ] Correspondence

                Takahiro Nishio, Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaharacho Shogoin Sakyo‐ku, Kyoto 606‐8507, Japan.

                Email: tnishio@ 123456kuhp.kyoto-u.ac.jp

                Author information
                https://orcid.org/0000-0002-9676-7235
                Article
                AGS312692 AGS-2023-0052.R1
                10.1002/ags3.12692
                10623981
                37927928
                dd823bd9-4f67-4d8b-b903-11214f28a5b1
                © 2023 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 08 April 2023
                : 21 February 2023
                : 03 May 2023
                Page count
                Figures: 2, Tables: 5, Pages: 16, Words: 11716
                Funding
                Funded by: Japan Society for the Promotion of Science , doi 10.13039/501100001691;
                Award ID: 21K16444
                Award ID: 22K08733
                Funded by: Takeda Science Foundation , doi 10.13039/100007449;
                Categories
                Review Article
                Review Articles
                Custom metadata
                2.0
                November 2023
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.4 mode:remove_FC converted:03.11.2023

                hepatocellular carcinoma,liver fibrosis,liver resection,portal hypertension,posthepatectomy liver failure

                Comments

                Comment on this article